A

Amgen

Makes biotech medicines for serious illnesses

Director – Scientific and Operations Intelligence - Obesity

Full-TimeUpdated on 10/24/2026
No salary listed
Expert
Bachelor's, Master's, PhD
Hyderabad, Telangana, India
In Person
Business & StrategyCorporate Strategy

About the job

Requirements
  • A doctorate degree, a master's degree, or a bachelor's degree and 18 or more years of relevant experience.
  • Proven experience in strategy, business insights, analytics, consulting, business operations, Medical Affairs, Clinical Development, R&D strategy, supply chain strategy, or related functions within the pharmaceutical, biotechnology, healthcare, or life sciences industry.
  • Demonstrated experience leading visible cross-functional initiatives in complex global organizations.
  • Strong understanding of pharmaceutical development, healthcare ecosystems, scientific and medical strategy, supply and operational readiness, and business decision-making processes.
  • Experience synthesizing large volumes of information into clear, actionable recommendations for senior leadership.
  • Proven ability to influence senior stakeholders and operate effectively in ambiguous, matrixed environments.
  • Experience building new capabilities, operating models, or teams from the ground up.
  • Ability to balance long-term capability building with near-term delivery priorities.
Responsibilities
  • Build the India-based capability that applies analytics and intelligence to scientific and operational priorities across Amgen's global obesity organization.
  • Define the operating cadence, stakeholder engagement model, work-product standards, and team operating model.
  • Proactively identify emerging business questions, surface issues that warrant leadership attention, and frame critical decisions requiring analytical support.
  • Expand the organization's use of analytics and intelligence into areas of growing business importance.
  • Build trusted partnerships across Medical Affairs, Clinical Development, R&D, Supply Chain, Operations, and related stakeholder groups.
  • Keep the capability aligned to senior leadership priorities so outputs sharpen choices, clarify trade-offs, and do not become a status-reporting layer.
  • Partner with Medical Affairs, Clinical Development, R&D, and evidence-generation leaders to address high-priority analytical questions and intelligence needs.
  • Synthesize scientific, clinical, and medical information into executive-ready recommendations and practical business implications.
  • Assess implications of emerging clinical data, regulatory developments, competitive activity, and scientific innovation on obesity strategy and execution.
  • Support leadership understanding of evolving treatment paradigms, patient needs, evidence gaps, and scientific innovation across obesity and related therapeutic areas.
  • Apply analytical rigor and structured problem solving to address emerging questions and evolving priorities across Medical Affairs, Clinical Development, and R&D.
  • Support analytical and intelligence needs related to supply chain, manufacturing, operations, launch readiness, and organizational preparedness.
  • Develop practical views of demand signals, supply readiness, and operational execution.
  • Partner with Supply Chain and Operations leaders to support scenario planning, risk mitigation, and readiness assessments.
  • Assess how operational risks, supply constraints, and launch timing may influence execution, near-term priorities, and strategic choices.
  • Support critical business decisions through early identification of execution risks and strategic dependencies.
  • Lead complex analytical initiatives requiring input from multiple stakeholders, teams, or business functions.
  • Structure ambiguous business questions, define the analytical approach, and guide work from problem framing through recommendation.
  • Synthesize diverse information into practical insights that help stakeholders evaluate options, understand trade-offs, and determine where additional analysis is needed.
  • Translate complex analyses into clear recommendations, implications, and actions for senior leaders.
  • Drive business impact through analytical rigor, sound judgment, and high-quality execution.
  • Monitor external developments that may influence obesity strategy, execution, operations, or future opportunities.
  • Assess implications of scientific, competitive, policy, healthcare-system, and market developments on business priorities.
  • Identify emerging trends, opportunities, and risks that warrant leadership attention.
  • Support stakeholders in evaluating potential business implications and response options.
  • Create practical mechanisms that improve awareness of important external developments.
  • Bring forward ideas that strengthen business performance, organizational effectiveness, and readiness for future growth.
  • Build, develop, and lead a high-performing India-based team focused on scientific and operational intelligence, analytical problem solving, and decision support.
  • Create an environment that promotes intellectual curiosity, analytical rigor, accountability, practical judgment, and ownership.
  • Coach and develop future leaders while strengthening strategic thinking, business acumen, executive communication, and stakeholder management capabilities.
  • Establish clear goals, performance expectations, and career development pathways that support organizational priorities and individual growth.
  • Foster an inclusive and collaborative culture that attracts, retains, and develops strong analytics and intelligence talent.
  • Encourage team members to think beyond assigned deliverables while building the judgment, communication, and business acumen needed to support senior stakeholders with confidence.
Desired Qualifications
  • An advanced degree in Business, Strategy, Analytics, Public Health, Life Sciences, Medicine, Pharmacy, Engineering, Economics, or a related field.
  • Exceptional strategic thinking, structured problem solving, executive communication, and storytelling skills.
  • Demonstrated success leading high-performing teams and developing future leaders.
  • Strong intellectual curiosity and passion for solving complex business problems.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.